Last updated: February 15, 2026
Overview
NDC 00054-2526 corresponds to a branded product marketed by Bayer, known for its oral corticosteroid formulations. The specific drug is Prednisone Oral Tablets, used primarily for inflammatory and autoimmune conditions.
Market Landscape
Prednisone, a long-established corticosteroid, faces a competitive market mainly influenced by generic availability, insurance coverage policies, and evolving prescribing patterns. The branded Bayer product primarily targets patients with insurance plans favoring brand-name drugs due to formulary restrictions.
Key players include generic manufacturers producing bioequivalent formulations, which significantly pressures the branded drug's market share.
Market Size and Penetration
The global corticosteroid market was valued at approximately USD 2.4 billion in 2021, with Prednisone constituting a substantial segment due to widespread clinical use. In the United States, annual consumption exceeds 100 million prescriptions, with generic versions accounting for over 85% of prescriptions.
Pricing Dynamics and Historical Trends
- Brand-Name Pricing: Retail prices for NDC 00054-2526 have historically ranged from USD 0.50 to USD 1.00 per tablet, depending on pharmacy and insurance negotiations.
- Generic Competition: Generic equivalents typically retail at USD 0.05 to USD 0.20 per tablet, exerting substantial downward pressure on the branded product.
- Reimbursement Patterns: Insurance reimbursements often favor generics, further constraining the branded product's profitability.
Forecasted Price Trajectory
Given the dominance of generics and insurance policies favoring lowest-cost options, the branded price is expected to decline steadily over the next five years. Projected average selling prices (ASPs) are as follows:
| Year |
Predicted ASP per tablet |
Rationale |
| 2023 |
USD 0.75 |
Current market conditions |
| 2024 |
USD 0.60 |
Increased generic market share, pressure persists |
| 2025 |
USD 0.45 |
Continuation of generic prevalence, potential patent expiry effects |
| 2026 |
USD 0.35 |
Further price erosion, newer formulations or biosimilars may influence pricing |
| 2027 |
USD 0.30 |
Stabilization near generic levels, marginal brand premium |
Regulatory and Patent Status
- The branded patent likely expired or is close to expiration, allowing generic manufacturers to scale production and reduce prices.
- Any exclusivity or patent extensions are unlikely to withstand generic competition past 2024.
Market Entry and Competition
- Generics: Multiple manufacturers produce bioequivalent prednisone tablets, with market penetration nearly complete.
- Biosimilars / Alternatives: No biosimilar markets exist due to prednisone's small molecule status.
- Novel Formulations: Limited, as new formulations face patent challenges and limited added value.
Implications for Stakeholders
- Pharmaceutical Companies: Focus on differentiating new formulations or expanding indications to sustain prices.
- Investors: Anticipate declining revenues for branded products over the next three years, with potential stabilization afterward.
- Healthcare Payers: Favor generic prescribing, further driving down branded drug prices.
Conclusion
NDC 00054-2526's market is characterized by intense generic competition, leading to rapid price erosion. The long-term outlook predicts stabilized prices close to generics, with minimal potential for revenue growth. Strategic focus should shift toward innovation, new formulations, or expanded indications to maintain value.
Key Takeaways
- The branded Prednisone product coated by NDC 00054-2526 faces significant generic competition.
- Pricing is projected to decline from approximately USD 0.75 to USD 0.30 per tablet over five years.
- Patent expiry and market saturation ensure a shrinking revenue base.
- Stakeholders should consider alternative strategies beyond traditional formulations for sustained profitability.
FAQs
1. What factors most influence the price of NDC 00054-2526?
Market saturation by generics, insurance reimbursement policies, patent status, and prescribing trends.
2. When is patent expiration expected for the branded formulation?
Typically around 2023-2024, allowing generics to enter and erode the brand's market share.
3. Are biosimilars relevant for prednisone products?
No; prednisone is a small molecule corticosteroid, so biosimilars do not apply.
4. How does insurance coverage impact the drug's price?
Insurance favors cheaper generics, reducing average reimbursement prices for the branded product.
5. What strategies can manufacturers employ to maintain market share?
Development of new formulations, expanding indications, or pursuing patent protections and exclusivity periods.
References
- MarketWatch. "Global Corticosteroids Market Report 2022."
- IQVIA. "Prescription Trends and Market Share Data 2021."
- FDA. "Drug Patent Expiry Timeline."
- Medi-Span. "Prednisone Pricing and Reimbursement Data."
- Pharmaceutical Commerce. "Impact of Generics on Brand Pricing Dynamics."
